{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:34:01Z","timestamp":1791182041333,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.canlet.2014.07.017","type":"journal-article","created":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T03:16:30Z","timestamp":1406862990000},"page":"115-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation"],"prefix":"10.1016","volume":"353","author":[{"given":"Yanli","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2014.07.017_b0005","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/ehm.10.42","article-title":"Pathogenesis, classification and treatment of mastocytosis: state of the art in and future perspectives","volume":"3","author":"Arock","year":"2010","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.canlet.2014.07.017_b0010","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","article-title":"Mast cell leukemia","volume":"121","author":"Georgin-Lavialle","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.07.017_b0015","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.07.017_b0020","first-page":"121","article-title":"Mastocytosis: state of the art. Pathobiology: journal of immunopathology","volume":"74","author":"Horny","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.canlet.2014.07.017_b0025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.23459","article-title":"Systemic mastocytosis in adults: 2012 update on diagnosis, risk stratification, and management","volume":"87","author":"Pardanani","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2014.07.017_b0030","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V95.2.726","article-title":"C-kit mutations in core binding factor leukemias","volume":"95","author":"Beghini","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.07.017_b0035","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000140630","article-title":"KIT and mastocytosis","volume":"119","author":"Lim","year":"2008","journal-title":"Acta Haematol."},{"key":"10.1016\/j.canlet.2014.07.017_b0040","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1007\/s00018-004-4189-6","article-title":"Signal transduction via the stem cell factor receptor\/c-Kit","volume":"61","author":"Ronnstrand","year":"2004","journal-title":"Cell. Mol. Life Sci.: CMLS"},{"key":"10.1016\/j.canlet.2014.07.017_b0045","doi-asserted-by":"crossref","first-page":"31461","DOI":"10.1074\/jbc.C300186200","article-title":"Structure of a c-kit product complex reveals the basis for kinase transactivation","volume":"278","author":"Mol","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2014.07.017_b0050","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood.V85.3.790.bloodjournal853790","article-title":"Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines","volume":"85","author":"Kitayama","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.07.017_b0055","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood.V83.9.2619.2619","article-title":"Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation","volume":"83","author":"Tsujimura","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.07.017_b0060","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2174\/156800907781386614","article-title":"Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders","volume":"7","author":"Patnaik","year":"2007","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.canlet.2014.07.017_b0065","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2011.05.006","article-title":"Tyrosine kinase inhibitors in the treatment of systemic mastocytosis","volume":"35","author":"Ustun","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.canlet.2014.07.017_b0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/ejh.12043","article-title":"Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression","volume":"90","author":"Verstovsek","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.canlet.2014.07.017_b0075","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin. Cancer Res.: Official J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.canlet.2014.07.017_b0080","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.11339","article-title":"Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT","volume":"92","author":"Gleixner","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2014.07.017_b0085","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3324\/haematol.2012.079202","article-title":"Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V","volume":"98","author":"Gleixner","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2014.07.017_b0090","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1038\/sj.onc.1210159","article-title":"Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate","volume":"26","author":"Kosmider","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2014.07.017_b0095","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood-2006-04-013805","article-title":"EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation","volume":"109","author":"Pan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.07.017_b0100","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1158\/1535-7163.MCT-13-0397","article-title":"Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing beta-catenin signaling","volume":"13","author":"Jin","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2014.07.017_b0105","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/0008-5472.CAN-09-3950","article-title":"Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species","volume":"70","author":"Jin","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2014.07.017_b0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1476-4598-13-17","article-title":"Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRalpha: roles of Mcl-1 and beta-catenin","volume":"13","author":"Jin","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2014.07.017_b0115","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/1521-1878(200011)22:11<961::AID-BIES1>3.0.CO;2-T","article-title":"Catenins, Wnt signaling and cancer","volume":"22","author":"Barker","year":"2000","journal-title":"BioEssays: News Rev. Mol. Cell. Dev. Biol."},{"key":"10.1016\/j.canlet.2014.07.017_b0120","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/382638a0","article-title":"Functional interaction of beta-catenin with the transcription factor LEF-1","volume":"382","author":"Behrens","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2014.07.017_b0125","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.leukres.2007.08.023","article-title":"KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia","volume":"32","author":"Kajiguchi","year":"2008","journal-title":"Leuk. Res."},{"key":"10.1016\/j.canlet.2014.07.017_b0130","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.canlet.2014.07.017_b0135","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.canlet.2014.07.017_b0140","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast-cell disease","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2014.07.017_b0145","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2014.07.017_b0150","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2006-07-032714","article-title":"Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412","volume":"109","author":"Aichberger","year":"2007","journal-title":"Blood"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514003541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514003541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T19:19:24Z","timestamp":1717183164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383514003541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0304383514003541"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2014.07.017","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2014.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}